

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GENERTEC UNIVERSAL MEDICAL GROUP COMPANY
LIMITED**

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTORS AND
INDEPENDENT NON-EXECUTIVE DIRECTORS
(2) APPOINTMENT OF NON-EXECUTIVE DIRECTORS AND
INDEPENDENT NON-EXECUTIVE DIRECTORS
AND
(3) CHANGES IN COMPOSITION OF THE REMUNERATION
COMMITTEE, THE NOMINATION COMMITTEE AND THE
STRATEGY COMMITTEE**

The Board announces that, with effect from 22 June 2022:

- (i) Mr. Zhao Yan resigned as the vice-chairman of the Board, a non-executive Director, a member of the Remuneration Committee and a member of the Strategy Committee;
- (ii) Mr. Che Lingyun resigned as a non-executive Director, a member of the Remuneration Committee and a member of the Nomination Committee;
- (iii) Mr. Han Demin resigned as an independent non-executive Director and a member of the Remuneration Committee; and

(iv) Mr. Liao Xinbo resigned as an independent non-executive Director and a member of the Nomination Committee.

The Board is pleased to announce that with effect from 22 June 2022:

(i) Mr. Chan Kai Kong was appointed as the vice-chairman of the Board, a non-executive Director, a member of the Remuneration Committee and a member of the Strategy Committee;

(ii) Mr. Xu Ming was appointed as a non-executive Director, a member of the Remuneration Committee and a member of the Nomination Committee;

(iii) Mr. Xu Zhiming was appointed as an independent non-executive Director and a member of the Remuneration Committee; and

(iv) Mr. Chan, Hiu Fung Nicholas was appointed as an independent non-executive Director and a member of the Nomination Committee.

RESIGNATION OF NON-EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of Genertec Universal Medical Group Company Limited (the “**Company**”) announces that it received the resignation letters from two non-executive Directors, being Mr. Zhao Yan (“**Mr. Zhao**”) and Mr. Che Lingyun (“**Mr. Che**”), and two independent non-executive Directors, being Mr. Han Demin (“**Mr. Han**”) and Mr. Liao Xinbo (“**Mr. Liao**”). With effect from 22 June 2022:

- (i) Mr. Zhao resigned as the vice-chairman of the Board, a non-executive Director, a member of the Board’s remuneration committee (the “**Remuneration Committee**”) and a member of the Board’s strategy committee (the “**Strategy Committee**”), due to his other work arrangements;
- (ii) Mr. Che resigned as a non-executive Director, a member of the Remuneration Committee and a member of the Board’s nomination committee (the “**Nomination Committee**”), due to his other work arrangements;
- (iii) Mr. Han resigned as an independent non-executive Director and a member of the Remuneration Committee, due to his other work arrangements; and
- (iv) Mr. Liao resigned as an independent non-executive Director and a member of the Nomination Committee, due to his other work arrangements.

Each of Mr. Zhao, Mr. Che, Mr. Han and Mr. Liao has confirmed that he has no disagreement with the Board, and is not aware of other matters in connection with his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Zhao, Mr. Che, Mr. Han and Mr. Liao for their valuable contributions to the Company during their respective tenure.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board is pleased to announce that, with effect from 22 June 2022, (i) Mr. Chan Kai Kong (陳啓剛先生) was appointed as the vice-chairman of the Board, a non-executive Director, a member of the Remuneration Committee and a member of the Strategy Committee; (ii) Mr. Xu Ming (徐明先生) was appointed as a non-executive Director, a member of the Remuneration Committee and a member of the Nomination Committee; (iii) Mr. Xu Zhiming (許志明先生) was appointed as an independent non-executive Director and a member of the Remuneration Committee; and (iv) Mr. Chan, Hiu Fung Nicholas (陳曉峰先生) was appointed as an independent non-executive Director and a member of the Nomination Committee.

The biographical details of the above newly appointed Directors are set out below:

Non-executive Directors

Mr. Chan Kai Kong (陳啓剛先生)

Mr. Chan Kai Kong, aged 52, has extensive experience in financing and investment. Mr. Chan has been a non-executive director of Frontier Services Group Limited (先豐服務集團有限公司), the shares of which are listed on the Stock Exchange (stock code: 0500), since February 2021. Mr. Chan joined CITIC Capital Holdings Limited (中信資本控股有限公司) in 2005, and he is the chief financial officer and a senior managing director. He is also an investment committee member of various funds of Trustar Capital, the private equity business of CITIC Capital Holdings Limited. Mr. Chan was a vice president of the direct investment department at Government of Singapore Investment Corporation (新加坡政府投資公司) from 2001 to 2005 and an investment professional at International Finance Corporation (國際金融公司) from 1997 to 2000. He previously worked for Deloitte and had corporate finance experience with both listed companies and merchant bank.

Mr. Chan obtained a master's degree in finance in 1997 from the London Business School (倫敦商學院) and a bachelor degree in business administration in 1991 from The Chinese University of Hong Kong.

Mr. Chan and the Company entered into an appointment letter on 22 June 2022, pursuant to which Mr. Chan has been appointed as a non-executive Director since 22 June 2022, and such appointment could be terminated by either Mr. Chan or the Company by giving not less than three months' notice in writing. Mr. Chan will hold office until completion of the next annual general meeting of the Company following his appointment, and will then be eligible for re-election at that general meeting. If Mr. Chan would be re-elected at the Company's next annual general meeting, he will be subject to the requirements under the articles of association of the Company regarding retirement by rotation and re-election at the annual general meeting of the Company. Pursuant to the appointment letter, Mr. Chan is not entitled to any remuneration during his term of service.

As at the date of this announcement, Mr. Chan has interest in 30,000 shares of the Company. Except as disclosed above, Mr. Chan did not (i) have any relationship with any Directors, senior management or substantial or controlling Shareholders; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Chan that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Chan's role as a non-executive Director.

Mr. Xu Ming (徐明先生)

Mr. Xu Ming, aged 57, has extensive experience in corporate governance. Mr. Xu has been the general manager of Genertec Hong Kong International Capital Limited (通用技術集團香港國際資本有限公司), a subsidiary of the Company's controlling shareholder, China General Technology (Group) Holding Company Limited (中國通用技術(集團)控股有限責任公司, "**GT-PRC**"), since September 2018. From August 2008 to February 2020, Mr. Xu served as a director of China Meheco Group Co., Ltd. (中國醫藥健康產業股份有限公司), the shares of

which are listed on the Shanghai Stock Exchange (stock code: 600056). From July 1998 to September 2018, Mr. Xu successively served as a department manager, a vice general manager and the general manager of the financial management department of GT-PRC.

Mr. Xu received a master degree in business administration (part-time) from Tsinghua University (清華大學) in January 2013 and a bachelor's degree in accounting from Beijing Institute of Business (北京商學院) in June 1988. Mr. Xu was qualified as a senior accountant (高級會計師) in August 2002 by Appraisal and Approval Committee for Professional & Technical Qualification of GT-PRC (通用技術集團專業技術資格評審委員會).

Mr. Xu and the Company entered into an appointment letter on 22 June 2022, pursuant to which Mr. Xu has been appointed as a non-executive Director since 22 June 2022, and such appointment could be terminated by either Mr. Xu or the Company by giving not less than three months' notice in writing. Mr. Xu will hold office until completion of the next annual general meeting of the Company following his appointment, and will then be eligible for re-election at that general meeting. If Mr. Xu would be re-elected at the Company's next annual general meeting, he will be subject to the requirements under the articles of association of the Company regarding retirement by rotation and re-election at the annual general meeting of the Company. Pursuant to the appointment letter, Mr. Xu is not entitled to any remuneration during his term of service.

As at the date of this announcement, except as disclosed above, Mr. Xu did not (i) have any relationship with any Directors, senior management or substantial or controlling Shareholders; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Xu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Xu's role as a non-executive Director.

Independent Non-executive Directors

Mr. Xu Zhiming (許志明先生)

Mr. Xu Zhiming, aged 60, has extensive experience in corporate governance. Mr. Xu has been (i) an independent non-executive director of Tianjin Capital Environmental Protection Group Company Limited (天津創業環保集團股份有限公司), the shares of which are listed on the Stock Exchange (stock code: 1065) and the Shanghai Stock Exchange (stock code: 600874), since November 2021, and (ii) an independent non-executive director of 東方證券股份有限公司, the shares of which are listed on the Stock Exchange (stock code: 3958) and the Shanghai Stock Exchange (stock code: 600958), since July 2016. Mr. Xu currently serves as a director of each of Donlink Group Co., Ltd. (東凌集團有限公司), Guangzhou Donlink Industrial Investment Group Co., Ltd. (廣州東凌實業投資集團有限公司), Beijing Lianhang Hezhong Media Technology Co., Ltd. (北京聯航合眾傳媒科技有限公司) and Beijing Baoxuan Culture Media Co., Ltd. (北京寶軒文化傳媒有限公司), and is a founding partner of China Broadband Capital (寬帶資本). From August 1999 to December 2001, Mr. Xu successively served as an executive director of China Resources Enterprise, Limited (華潤創業有限公司), an executive director of China Resources (Beijing) Land Limited (華潤北京置地有限公司), the managing director and chief operating officer of China Resources Logic Limited (華潤勵致有限公司). From January 2002 to May 2005, Mr. Xu successively served as a senior consultant of TOM Group Ltd. (TOM集團有限公司), and an executive director and chief operating officer of TOM Online Inc. (TOM在線有限公司).

Mr. Xu received a doctoral degree in economics from University of Manchester in the United Kingdom (英國曼徹斯特大學) in February 1993, a master's degree in industrial economy from Chinese Academy of Social Science (中國社會科學院) in July 1986 and a bachelor's degree in astrophysics from Peking University (北京大學) in July 1983.

Mr. Xu and the Company entered into an appointment letter on 22 June 2022, pursuant to which Mr. Xu was appointed as an independent non-executive Director since 22 June 2022, and such appointment could be terminated by either Mr. Xu or the Company by giving not less than three months' notice in writing. Mr. Xu will hold office until completion of the next annual general meeting of the Company following his appointment, and will then be eligible for re-election at that general meeting. If Mr. Xu would be re-elected at the Company's next annual general meeting, he will be subject to the requirements under the articles of association of the Company regarding retirement by rotation and re-election at the annual general meeting of the Company. Mr. Xu, pursuant to the appointment letter, is entitled to a director's fee of HK\$400,000 per annum which was determined by the Board with reference to his duties and responsibilities as well as prevailing market rates.

As at the date of this announcement, except as disclosed above, Mr. Xu did not (i) have any relationship with any Directors, senior management or substantial or controlling Shareholders; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Xu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Xu's role as an independent non-executive Director.

Mr. Chan, Hiu Fung Nicholas (陳曉峰先生) MH, JP

Mr. Chan, Hiu Fung Nicholas, aged 48, is currently a practising solicitor in Hong Kong and has over 20 years of experience in the legal practice. Mr. Chan has been working at Squire Patton Boggs (翰宇國際律師事務所) since April 1999 and has been a partner of it since September 2005. Prior to that, he served as an associate at Deacons (香港的近律師事務所). Mr. Chan has ample listed company board experience having served as (i) an independent non-executive director of Million Cities Holdings Limited (萬城控股有限公司), a company listed on the Stock Exchange (stock code: 2892) since December 2021, (ii) an independent non-executive director of Pangeaea Connectivity Technology Limited (環聯連訊科技有限公司), a company listed on the Stock Exchange (stock code: 1473) since January 2021, (iii) an independent non-executive director of Q P Group Holdings Limited (雋思集團控股有限公司), a company listed on the Stock Exchange (stock code:1412), since December 2019, and (iv) an independent non-executive director of Sa Sa International Holdings Limited (莎莎國際控股有限公司), a company listed on the Stock Exchange (stock code:0178), since September 2019.

Mr. Chan graduated from the University of Melbourne, Australia (澳大利亞墨爾本大學), in March 1997 with a degree of bachelor of laws and a degree of bachelor of science. Mr. Chan was admitted as a solicitor in Hong Kong in May 1999. He was also admitted as a solicitor of Australia Capital Territory, the State of Victoria in Australia and England and Wales in June 1997, October 2000 and October 2007, respectively. He was appointed as a China-Appointed Attesting Officer (中國委託公證人) by Ministry of Justice of the People's Republic of China (中華人民共和國司法部).

Mr. Chan has been appointed to serve as the Director to lead the operations of AALCO Hong Kong Regional Arbitration Centre since May 2022. The centre was established by agreement between the Central People's Government of the People's Republic of China and the Asian-African Legal Consultative Organization, an intergovernmental organization established in 1956 and now with 47 member countries.

Mr. Chan is appointed for a three years term to serve as a council member of The Chinese University of Hong Kong from June 2022. Mr. Chan served as a council member of The Hong Kong University of Science and Technology (香港科技大学) from April 2016 to March 2022. He was appointed as a member to the Legal Aid Services Council (法律援助服务局) for a term of two years from September 2018 and was re-appointed to serve for another term of two years from September 2020. Mr. Chan has been appointed as a member of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital (青山醫院及小欖醫院管治委員會) since April 2019. He served as chairman of eBRAM International Online Dispute Resolution Centre Limited (一邦國際網上仲調中心), an independent and not-for-profit organisation under Hong Kong law as a company limited by guarantee. Mr. Chan was appointed as a representative of the 13th National People's Congress of the PRC in 2019. He was awarded the Medal of Honour from the Government of the HKSAR (香港特別行政區政府榮譽勳章) in July 2016 and has also been appointed as a Justice of the Peace (太平紳士) by the Government of the HKSAR in July 2021.

Mr. Chan and the Company entered into an appointment letter on 22 June 2022, pursuant to which Mr. Chan was appointed as an independent non-executive Director since 22 June 2022, and such appointment could be terminated by either Mr. Chan or the Company by giving not less than three months' notice in writing. Mr. Chan will hold office until completion of the next annual general meeting of the Company following his appointment, and will then be eligible for re-election at that general meeting. If Mr. Chan would be re-elected at the Company's next annual general meeting, he will be subject to the requirements under the articles of association of the Company regarding retirement by rotation and re-election at the annual general meeting of the Company. Mr. Chan, pursuant to the appointment letter, is entitled to a director's fee of HK\$400,000 per annum which was determined by the Board with reference to his duties and responsibilities as well as prevailing market rates.

As at the date of this announcement, except as disclosed above, Mr. Chan did not (i) have any relationship with any Directors, senior management or substantial or controlling Shareholders; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships

in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Chan that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Chan's role as an independent non-executive Director.

CHANGES IN COMPOSITION OF THE REMUNERATION COMMITTEE, THE NOMINATION COMMITTEE AND THE STRATEGY COMMITTEE

Following the resignation of Mr. Zhao, Mr. Che, Mr. Han and Mr. Liao, and upon appointments of Mr. Chan Kai Kong, Mr. Xu Ming, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas, the composition of the Remuneration Committee, the Nomination Committee and the Strategy Committee are as follows:

The Remuneration Committee:

- Mr. Chow Siu Lui (chairman of the committee and independent non-executive Director)
- Mr. Chan Kai Kong (non-executive Director)
- Mr. Xu Ming (non-executive Director)
- Mr. Li Yinquan (independent non-executive Director)
- Mr. Xu Zhiming (independent non-executive Director)

The Nomination Committee:

- Ms. Peng Jiahong (chairwoman of the committee and executive Director)
- Mr. Xu Ming (non-executive Director)
- Mr. Li Yinquan (independent non-executive Director)
- Mr. Chow Siu Lui (independent non-executive Director)
- Mr. Chan, Hiu Fung Nicholas (independent non-executive Director)

The Strategy Committee:

- Ms. Peng Jiahong (chairwoman of the committee and executive Director)
- Mr. Chan Kai Kong (non-executive Director)

- Mr. Zhu Ziyang (non-executive Director)

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 22 June 2022

As at the date of this announcement, the executive Directors are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Mr. Yu Gang; the non-executive Directors are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.